Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Von Willebrand Factor

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    94 result(s) found for: Von Willebrand Factor. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2008-004922-18 Sponsor Protocol Number: CSLCT-BIO-08-54 Start Date*: 2009-04-16
    Sponsor Name:CSL Behring GmbH
    Full Title: An Open-label, Multi-centre Study to Assess the Pharmacokinetics, Efficacy and Safety of Biostate® in Subjects with Von Willebrand Disease.
    Medical condition: Von Willebrand Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10047715 Von Willebrand's disease LLT
    9.1 10047715 Von Willebrand's disease PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2012-003450-92 Sponsor Protocol Number: IG1005 Start Date*: 2013-11-23
    Sponsor Name:Instituto Grifols S.A.
    Full Title: EVALUATION OF THE PHARMACOKINETIC PROFILE, CLINICAL EFFICACY AND SAFETY OF THE VON WILLEBRAND FACTOR CONTAINED IN FANHDI® (DOUBLE-INACTIVATED HUMAN ANTI-HEMOPHILIC FACTOR) IN PEDIATRIC PATIENTS WIT...
    Medical condition: Severe von Willebrand disease including types I, II, and III with VWF:RCof <15-20%
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022891 - Investigations 10068986 Von Willebrand's factor activity decreased PT
    14.1 10010331 - Congenital, familial and genetic disorders 10047715 Von Willebrand's disease PT
    14.1 10010331 - Congenital, familial and genetic disorders 10055168 Von Willebrand's factor deficiency LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-001426-84 Sponsor Protocol Number: WIL-14 Start Date*: 2006-02-09
    Sponsor Name:Octapharma AG
    Full Title: CLINICAL STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND IMMUNOGENICITY OF WILATE IN CHILDREN < 6 YEARS OF AGE WITH INHERITED VON WILLEBRAND DISEASE
    Medical condition: Inherited von Willebrand Disease
    Disease: Version SOC Term Classification Code Term Level
    8.0 10047715 PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2007-004116-32 Sponsor Protocol Number: Protocol WIL1-0609 Start Date*: 2008-12-03
    Sponsor Name:LFB BIOTECHNOLOGIES
    Full Title: EFFICACY AND SAFETY STUDY OF WILFACTIN ADMINISTERED BY CONTINUOUS INFUSION IN PATIENTS WITH SEVERE VON WILLEBRAND DISEASE UNDERGOING MAJOR SURGICAL PROCEDURES
    Medical condition: Severe von Willebrand disease patients undergoing elective major surgery
    Disease: Version SOC Term Classification Code Term Level
    9.1 10055168 Von Willebrand's factor deficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-001746-17 Sponsor Protocol Number: 42-73-406/ WIL1-0406 Start Date*: 2005-04-13
    Sponsor Name:LFB BIOTECHNOLOGIES
    Full Title: EFFICACY AND SAFETY STUDY OF vWF SD-35-DH (WILFACTIN) IN PATIENTS UNDER LONG TERM PROPHYLAXIS
    Medical condition: von Willebrand disease
    Disease: Version SOC Term Classification Code Term Level
    10047715
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-005401-20 Sponsor Protocol Number: CSLCT-BIO-03-97 Start Date*: 2015-01-30
    Sponsor Name:CSL Limited
    Full Title: An Open-label, Multi-centre Study to Assess the Efficacy and Safety of Biostate® in Patients With von Willebrand's Disease (VWD)
    Medical condition: Von Willebrand's disease (VWD)
    Disease: Version SOC Term Classification Code Term Level
    17.1 10010331 - Congenital, familial and genetic disorders 10047715 Von Willebrand's disease PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-001910-25 Sponsor Protocol Number: WIL-21 Start Date*: 2008-07-17
    Sponsor Name:Octapharma AG
    Full Title: Pharmacokinetics of WILATE® and Haemate® P in von Willebrand type 3 patients - a prospective, randomised, controlled, open-labelled, 2-arm cross-over study
    Medical condition: Inherited von Willebrand Disease (VWD) type 3
    Disease: Version SOC Term Classification Code Term Level
    9.1 10047715 Von Willebrand's disease LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: View results
    EudraCT Number: 2004-005051-34 Sponsor Protocol Number: 42-73-305 / WIL1-0305 Start Date*: 2005-04-18
    Sponsor Name:LFB BIOTECHNOLOGIES
    Full Title: Efficacy and safety study of vWF SD-35-DH (WILFACTIN) in children under 6 years of age
    Medical condition: Von Willebrand disease
    Disease: Version SOC Term Classification Code Term Level
    10047715
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003305-25 Sponsor Protocol Number: CSLCT-BIO-12-83 Start Date*: 2015-07-07
    Sponsor Name:CSL Behring GmbH
    Full Title: An Open-label, Multi-centre Post-marketing Study to Assess the Efficacy and Safety of Voncento® in Subjects with Von Willebrand Disease
    Medical condition: Von Willebrand Disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 10010331 - Congenital, familial and genetic disorders 10047715 Von Willebrand's disease PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) AT (Completed) IE (Completed) PL (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2016-001478-14 Sponsor Protocol Number: 071301 Start Date*: Information not available in EudraCT
    Sponsor Name:Baxalta Innovations GmbH
    Full Title: A PROSPECTIVE, PHASE 3, OPEN LABEL, INTERNATIONAL MULTICENTER STUDY ON EFFICACY AND SAFETY OF PROPHYLAXIS WITH rVWF IN SEVERE VON WILLEBRAND DISEASE
    Medical condition: Hereditary severe von Willebrand Disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 10010331 - Congenital, familial and genetic disorders 10047715 Von Willebrand's disease PT
    19.0 10010331 - Congenital, familial and genetic disorders 10055168 Von Willebrand's factor deficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed) CZ (Completed) NL (Completed) ES (Completed) DE (Completed) FI (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-024108-84 Sponsor Protocol Number: 071001 Start Date*: 2011-10-31
    Sponsor Name:Baxter Innovations GmbH
    Full Title: A PHASE 3 CLINICAL STUDY TO DETERMINE THE PHARMACOKINETICS, SAFETY AND EFFICACY OF rVWF:rFVIII and rVWF IN THE TREATMENT OF BLEEDING EPISODES IN SUBJECTS DIAGNOSED WITH VON WILLEBRAND DISEASE
    Medical condition: Von Willebrand Disease
    Disease: Version SOC Term Classification Code Term Level
    16.0 10010331 - Congenital, familial and genetic disorders 10047715 Von Willebrand's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) SE (Completed) AT (Completed) NL (Completed) BE (Completed) BG (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-004868-69 Sponsor Protocol Number: AP7000_1-4002 Start Date*: 2005-03-07
    Sponsor Name:ZLB Behring LLC
    Full Title: Study of Safety and Efficacy of Antihemophilic Factor / von Willebrand Factor Complex (Humate-P®) Using Individualized Dosing in Pediatric and Adult Surgical Subjects with von Willebrand’s Disease
    Medical condition: Von Willebrand’s disease (VWD) is a common hereditary bleeding disorder. The impaired formation and adhesion of the initial platelet plug is reflected in the prolonged skin bleeding time. In addit...
    Disease: Version SOC Term Classification Code Term Level
    7.1 10047715 LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2010-021162-30 Sponsor Protocol Number: Wil-24 Start Date*: 2011-12-20
    Sponsor Name:Octapharma AG
    Full Title: Prospective, Open-Label, Multi-Center, Phase III Clinical Study To Investigate The Efficacy And Safety Of Human Factor VWF/VIII Concentrate (Wilate®) In Subjects With Inherited Von Willebrand Disea...
    Medical condition: Surgery in Inherited Von Willebrand Disease (VWD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10047715 Von Willebrand's disease PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-000664-85 Sponsor Protocol Number: 8VWF03 Start Date*: 2006-12-19
    Sponsor Name:Bio Products Laboratory
    Full Title: An Open Multi-centre Study to Investigate the Safety and Efficacy of OPTIVATE®, a High Purity, Dual Inactivated Factor VIII and von Willebrand Factor Concentrate, in Patients with von Willebrand Di...
    Medical condition: von Willebrand disease
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-017753-34 Sponsor Protocol Number: CSLCT-BIO-08-52 Start Date*: 2010-07-09
    Sponsor Name:CSL Behring GmbH
    Full Title: A Phase III Open-label, Multi-centre Study to Assess the Pharmacokinetics, Efficacy, and Safety of Biostate® in Paediatric Subjects with von Willebrand Disease.
    Medical condition: Von Willebrand Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10047715 Von Willebrand's disease PT
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2006-000663-28 Sponsor Protocol Number: 8VWF01 Start Date*: Information not available in EudraCT
    Sponsor Name:Bio Products Laboratory
    Full Title: An open multi-centre study in patients with von Willebrand Disease to investigate the pharmacokinetics, efficacy and safety of Optivate, a high purity, dual inactivated Factor VIII and Von Willebra...
    Medical condition: von Willebrands Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10047715 Von Willebrand's disease LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Ongoing) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-017301-11 Sponsor Protocol Number: CSLCT-BIO-09-64 Start Date*: 2010-09-20
    Sponsor Name:CSL Behring GmbH
    Full Title: An Open-Label, Multi-Centre Extension Study to Assess the Efficacy and Safety of Biostate® in Paediatric, Adolescent, and Adult Subjects with Von Willebrand Disease who Completed Clinical Studies C...
    Medical condition: Von Willebrand's Disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10010331 - Congenital, familial and genetic disorders 10047715 Von Willebrand's disease PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) PL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001383-23 Sponsor Protocol Number: PROWILL Start Date*: 2006-06-30
    Sponsor Name:FONDAZIONE CENTRO EMOFILIA E TROMBOSI ANGELO BIANCHI BONOMI
    Full Title: Efficacy, safety and pharmaco-economic assessment of secondary long term prophylaxis with highly purified, standardized, doubly virus inactivated FVIII/VWF concentrates in patients with severe, inh...
    Medical condition: patients with severe inherited VWD unresponsive to DDAVP and with frequent bleedings
    Disease: Version SOC Term Classification Code Term Level
    8.1 10047715 Von Willebrand's disease PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) GB (Completed) ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-003575-38 Sponsor Protocol Number: 071101 Start Date*: 2015-01-07
    Sponsor Name:Baxalta Innovations GmbH
    Full Title: A PHASE 3 PROSPECTIVE, MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF rVWF WITH OR WITHOUT ADVATE IN ELECTIVE SURGICAL PROCEDURES IN SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE
    Medical condition: Hereditary severe von Willebrand Disease in adult patients who will undergo major and minor elective surgical procedures
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004850 10055168 Von Willebrand's factor deficiency LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) IT (Completed) CZ (Completed) GB (Completed) NL (Completed) ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001631-46 Sponsor Protocol Number: NL65876.078.18 Start Date*: 2019-02-14
    Sponsor Name:Erasmus University Medical Center
    Full Title: Implementation of pharmacokinetic-guided dosing of DDAVP and VWF-containing concentrates in von Willebrand disease
    Medical condition: Von Willebrand disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10055168 Von Willebrand's factor deficiency LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 21:40:50 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA